Literature DB >> 26344061

Hospitalisation rates and associated factors in community-based cohorts of HIV-infected and -uninfected gay and bisexual men.

C L Moore1, A E Grulich1, G Prestage1,2, H F Gidding3, F Jin1, L Mao4, K Petoumenos1, I B Zablotska1, I M Poynten1, M G Law1, J Amin1.   

Abstract

OBJECTIVES: There is evidence that HIV-positive patients are suffering from a greater burden of morbidity as they age due to nonAIDS-related complications. To date it has been difficult to determine what part of this excess risk is due to the health effects of HIV, its treatment or to lifestyle factors common to gay and bisexual men (GBM). We calculated overall and cause-specific hospitalisation rates and risk factors for hospitalisations in HIV-negative and HIV-positive cohorts of GBM and compare these with rates in the general male population.
METHODS: We conducted a record linkage study, linking two cohorts of HIV-negative (n = 1325) and HIV-positive (n = 557) GBM recruited in Sydney, New South Wales (NSW), Australia with the NSW hospital discharge data register. We compared rates of hospitalisation in the two cohorts and risk factors for hospitalisation using random-effects Poisson regression methods. Hospitalisation rates for each cohort were further compared with those in the general male population using indirect standardisation.
RESULTS: We observed 2032 hospitalisations in the HIV-negative cohort during 13,016 person-years (PYs) [crude rate: 15.6/100 PYs (95% CI: 14.9-16.3)] and 2130 hospitalisations in the HIV-positive cohort during 5571 PYs [crude rate: 38.2/100 PYs (95% CI: 36.6-39.9)]. HIV-positive individuals had an increased risk of hospitalisation compared with the HIV-negative individuals [adjusted-IRR: 2.34 (95% CI: 1.91-2.86)] and the general population [SHR: 1.45 (95% CI: 1.33-1.59)]. Hospitalisation rates were lower in the HIV-negative cohort compared with the general population [SHR: 0.72 (95% CI: 0.67-0.78)]. The primary causes of hospitalisation differed between groups.
CONCLUSIONS: HIV-positive GBM continue to experience excess morbidity compared with HIV-negative GBM men and the general population. HIV-negative GBM had lower morbidity compared with the general male population suggesting that GBM identity does not confer excess risk.
© 2015 British HIV Association.

Entities:  

Keywords:  HIV; cohort studies; homosexuality; hospitalisation; medical record linkage

Mesh:

Year:  2015        PMID: 26344061      PMCID: PMC4779743          DOI: 10.1111/hiv.12312

Source DB:  PubMed          Journal:  HIV Med        ISSN: 1464-2662            Impact factor:   3.180


  29 in total

1.  Behavioural surveillance among gay men in Australia: methods, findings and policy implications for the prevention of HIV and other sexually transmissible infections.

Authors:  Iryna B Zablotska; Susan Kippax; Andrew Grulich; Martin Holt; Garrett Prestage
Journal:  Sex Health       Date:  2011-09       Impact factor: 2.706

2.  Recreational drug use, polydrug use, and sexual behaviour in HIV-diagnosed men who have sex with men in the UK: results from the cross-sectional ASTRA study.

Authors:  Marina Daskalopoulou; Alison Rodger; Andrew N Phillips; Lorraine Sherr; Andrew Speakman; Simon Collins; Jonathan Elford; Margaret A Johnson; Richard Gilson; Martin Fisher; Ed Wilkins; Jane Anderson; Jeffrey McDonnell; Simon Edwards; Nicky Perry; Rebecca O'Connell; Monica Lascar; Martin Jones; Anne M Johnson; Graham Hart; Alec Miners; Anna-Maria Geretti; William J Burman; Fiona C Lampe
Journal:  Lancet HIV       Date:  2014-09-07       Impact factor: 12.767

3.  Cancer survivorship and sexual orientation.

Authors:  Ulrike Boehmer; Xiaopeng Miao; Al Ozonoff
Journal:  Cancer       Date:  2011-05-09       Impact factor: 6.860

4.  Same-sex sexual behavior and psychiatric disorders: findings from the Netherlands Mental Health Survey and Incidence Study (NEMESIS).

Authors:  T G Sandfort; R de Graaf; R V Bijl; P Schnabel
Journal:  Arch Gen Psychiatry       Date:  2001-01

5.  A population-based study of sexual orientation identity and gender differences in adult health.

Authors:  Kerith J Conron; Matthew J Mimiaga; Stewart J Landers
Journal:  Am J Public Health       Date:  2010-06-01       Impact factor: 9.308

6.  Risk factors for human herpesvirus 8 infection among adults in the United States and evidence for sexual transmission.

Authors:  Eric A Engels; Jonnae O Atkinson; Barry I Graubard; Geraldine M McQuillan; Christine Gamache; Georgina Mbisa; Silvia Cohn; Denise Whitby; James J Goedert
Journal:  J Infect Dis       Date:  2007-06-04       Impact factor: 5.226

7.  Revised surveillance case definitions for HIV infection among adults, adolescents, and children aged <18 months and for HIV infection and AIDS among children aged 18 months to <13 years--United States, 2008.

Authors:  Eileen Schneider; Suzanne Whitmore; Kathleen M Glynn; Kenneth Dominguez; Andrew Mitsch; Matthew T McKenna
Journal:  MMWR Recomm Rep       Date:  2008-12-05

8.  Rates of hospitalizations and associated diagnoses in a large multisite cohort of HIV patients in the United States, 1994-2005.

Authors:  Kate Buchacz; Rose K Baker; Anne C Moorman; James T Richardson; Kathleen C Wood; Scott D Holmberg; John T Brooks
Journal:  AIDS       Date:  2008-07-11       Impact factor: 4.177

9.  Differences between HIV-positive gay men who 'frequently', 'sometimes' or 'never' engage in unprotected anal intercourse with serononconcordant casual partners: positive Health cohort, Australia.

Authors:  P Rawstorne; A Fogarty; J Crawford; G Prestage; J Grierson; A Grulich; S Kippax
Journal:  AIDS Care       Date:  2007-04

10.  Cancer in a population-based cohort of men and women in registered homosexual partnerships.

Authors:  Morten Frisch; Else Smith; Andrew Grulich; Christoffer Johansen
Journal:  Am J Epidemiol       Date:  2003-06-01       Impact factor: 4.897

View more
  1 in total

1.  Poor record linkage sensitivity biased outcomes in a linked cohort analysis.

Authors:  Cecilia L Moore; Heather F Gidding; Matthew G Law; Janaki Amin
Journal:  J Clin Epidemiol       Date:  2016-02-02       Impact factor: 6.437

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.